Yıl: 2022 Cilt: 10 Sayı: 3 Sayfa Aralığı: 235 - 240 Metin Dili: Türkçe DOI: 10.4274/nkmj.galenos.2022.96530 İndeks Tarihi: 17-10-2022

Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki

Öz:
Amaç: Magnezyum, kardiyovasküler hastalıklar başta olmak üzere birçok kronik hastalıkla ilişkilendirilmektedir. Bu çalışmanın amacı, serum magnezyum düzeyi, plazma aterojenik indeksi (PAİ) ve glomerüler filtrasyon hızı (GFH) arasındaki ilişkinin değerlendirilmesidir. Gereç ve Yöntem: Çalışmaya dahil edilen 214 hastanın verileri retrospektif olarak incelendi. Tahmini GFH 60 mL/dakika/1,73 m2 ve üzerinde olanlar “yüksek GFH grubu”, 60 mL/dakika/1,73 m2 ’den düşük olanlar “düşük GFH grubu” olarak gruplandırıldı. Serum trigliserit düzeyinin serum yüksek yoğunluklu lipoprotein düzeyine oranının logaritması alınarak PAİ hesaplandı. Bulgular: yüksek GFH grubunda 72, düşük GFH grubunda 142 hasta yer aldı. Serum magnezyum düzeyi ve PAİ açısından gruplar arasında farklılık saptanmadı. Tüm popülasyonda serum magnezyum düzeyi ile ilişkili faktörler incelendiğinde, sadece PAİ ile magnezyum arasında negatif yönde bir ilişki saptandı [Odds ratio (OR): -0,212]. Yine tüm popülasyonda PAİ ile ilişkili faktörler incelendiğinde, PAİ ile serum magnezyum düzeyi arasında negatif (OR: -0,189); vücut kitle indeksi, sistolik kan basıncı ve serum ürik asit düzeyi arasında pozitif yönde bir ilişki saptandı (sırasıyla; OR: 0,154; 0,276; 0,165). Gerek PAİ, gerekse magnezyum düzeyleri ile tahmini glomerüler filtrasyon hızı arasında ilişki saptanmadı. Sonuç: Serum magnezyum düzeyi ile PAİ arasındaki ters yönlü ilişki, hipomagnezeminin aterojenite ile ilişkisine dair genel literatür bilgisi ile uyumludur. PAİ ve serum magnezyum düzeyi ile GFH arasında bir ilişkinin saptanmamış olması, hasta sayısının azlığına bağlanabilir.
Anahtar Kelime:

The Relationship Between Serum Magnesium Level, Plasma Atherogenic Index and Glomerular Filtration Rate

Öz:
Aim: Magnesium is associated with many chronic diseases, especially cardiovascular diseases. The purpose of this study is to evaluate the relationship between serum magnesium level, glomerular filtration rate (GFR) and atherogenic index of plasma (AIP). Materials and Methods: The data of 214 patients included in the study were analyzed retrospectively. Those with an estimated GFR of 60 mL/ minute/1.73 m2 and above were grouped as the “high GFR group”, and those with an estimated GFR of less than 60 mL/minute/1.73 m2 were grouped as the “low GFR group”. AIP was calculated by taking the logarithm of the ratio of serum triglyceride level to serum high-density lipoprotein level. Results: There were 72 patients in the high GFR group and 142 patients in the low GFR group. There was no difference between the groups in terms of serum magnesium level and AIP. The factors related to serum magnesium level and AIP were investigated in the whole study population. A negative correlation was found between serum magnesium level and AIP [Odds ratio (OR): -0.212]. When the factors associated with AIP were examined, AIP was found to be negatively correlated with serum magnesium level (OR: -0.189) whereas positively correlated with body mass index, systolic blood pressure and serum uric acid level (OR: 0.154; 0.276; 0.165, respectively). There was no relationship between AIP and magnesium levels and GFR. Conclusion: The inverse relationship between serum magnesium level and AIP is consistent with the literature on the relationship between hypomagnesemia and atherogenicity. The lack of a relationship between AIP and serum magnesium level and GFR may be attributed to the small number of patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294:1-26.
  • Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin Dial. 2015;28:564-77.
  • Orlova S, Dikke G, Pickering G, Konchits S, Starostin K, Bevz A. Magnesium Deficiency Questionnaire: A New Non-Invasive Magnesium Deficiency Screening Tool Developed Using Real-World Data from Four Observational Studies. Nutrients. 2020;12:2062.
  • Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 2007;458:48-56.
  • Zhang W, Iso H, Ohira T, Date C, Tamakoshi A; JACC Study Group. Associations of dietary magnesium intake with mortality from cardiovascular disease: the JACC study. Atherosclerosis. 2012;221:587-95.
  • Nielsen FH. Magnesium deficiency and increased inflammation: current perspectives. J Inflamm Res. 2018;11:25-34.
  • Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, et al. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021;13:320.
  • Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother. 1994;28:220-6.
  • Chrysant SG, Chrysant GS. Association of hypomagnesemia with cardiovascular diseases and hypertension. Int J Cardiol Hypertens. 2019;1:100005.
  • Schutten JC, Joosten MM, de Borst MH, Bakker SJL. Magnesium and Blood Pressure: A Physiology-Based Approach. Adv Chronic Kidney Dis. 2018;25:244-50.
  • Long M, Zhu X, Wei X, Zhao D, Jiang L, Li C, et al. Magnesium in renal fibrosis. Int Urol Nephrol. 2022;54:1881-9.
  • Biyik Z, Yavuz YC, Altintepe L. Association between serum magnesium and anemia in patients with chronic kidney disease. Int Urol Nephrol. 2020;52:1935-41.
  • Azem R, Daou R, Bassil E, Anvari EM, Taliercio JJ, Arrigain S, et al. Serum magnesium, mortality and disease progression in chronic kidney disease. BMC Nephrol. 2020;21:49.
  • Xiong J, He T, Wang M, Nie L, Zhang Y, Wang Y, et al. Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and endstage renal disease patients: a systematic review and meta-analysis. J Nephrol. 2019;32:791-802.
  • Sakaguchi Y. The emerging role of magnesium in CKD. Clin Exp Nephrol. 2022;26:379-84.
  • Joosten MM, Gansevoort RT, Bakker SJ; PREVEND Study Group. Low plasma magnesium and risk of developing chronic kidney disease: results from the PREVEND Study. Kidney Int. 2015;87:1262-3.
  • Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, et al. Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States. J Am Heart Assoc. 2018;7:e007462.
  • Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006;17(4 Suppl 2):S145-7.
  • Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26:1402-7.
  • Găman MA, Dobrică EC, Cozma MA, Antonie NI, Stănescu AMA, Găman AM, et al. Crosstalk of Magnesium and Serum Lipids in Dyslipidemia and Associated Disorders: A Systematic Review. Nutrients. 2021;13:1411.
  • Cambray S, Ibarz M, Bermudez-Lopez M, Marti-Antonio M, Bozic M, Fernandez E, et al. Magnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness. Nutrients. 2020;12:2631.
  • Tautu OF, Darabont R, Onciul S, Deaconu A, Comanescu I, Andrei RD, et al. New cardiovascular risk factors and their use for an accurate cardiovascular risk assessment in hypertensive patients. Maedica (Bucur). 2014;9:127-34.
  • Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34:583-8.
  • Shen S, Lu Y, Qi H, Li F, Shen Z, Wu L, et al. Association between ideal cardiovascular health and the atherogenic index of plasma. Medicine (Baltimore). 2016;95:e3866.
  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
  • Galán Carrillo I, Vega A, Goicoechea M, Shabaka A, Gatius S, Abad S, et al. Impact of Serum Magnesium Levels on Kidney and Cardiovascular Prognosis and Mortality in CKD Patients. J Ren Nutr. 2021;31:494-502.
  • Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28:269-77.
  • Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5(Suppl 1):i52-i61.
  • Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007;68:222-7.
  • Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, et al. Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res. 2004;17:102-8.
  • Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol. 2008;40:1075-82.
  • Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol. 2012;36:228-37.
  • Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, et al. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovasc Drugs Ther. 2021;35:479-489.
  • Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6:287-96.
  • Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24:46-53.
  • Zhou Y, Shang X. Usefulness of atherogenic index of plasma for estimating reduced eGFR risk: insights from the national health and nutrition examination survey. Postgrad Med. 2021;133:278-85.
  • Chang Y, Li Y, Guo X, Guo L, Sun Y. Atherogenic Index of Plasma Predicts Hyperuricemia in Rural Population: A Cross-Sectional Study from Northeast China. Int J Environ Res Public Health. 2016;13:879.
  • Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 2018;17:197.
  • Wang T, Wang L, Ma N, Gu S, Jiang D, Li J, et al. Whole-blood magnesium and blood lipids are individually and jointly associated with an elevated likelihood of youngsters being overweight or obese: A matched case control study using the propensity score. Nutrition. 2022;93:111425.
  • Dey R, Rajappa M, Parameswaran S, Revathy G. Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk. Clin Exp Nephrol. 2015;19:1054-61.
APA Even Ö, ÇELIKKOL A, Bayrakci N, Karabacak V, özkan g (2022). Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. , 235 - 240. 10.4274/nkmj.galenos.2022.96530
Chicago Even Özge,ÇELIKKOL ALIYE,Bayrakci Nergiz,Karabacak Veli Yakup,özkan gülsu Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. (2022): 235 - 240. 10.4274/nkmj.galenos.2022.96530
MLA Even Özge,ÇELIKKOL ALIYE,Bayrakci Nergiz,Karabacak Veli Yakup,özkan gülsu Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. , 2022, ss.235 - 240. 10.4274/nkmj.galenos.2022.96530
AMA Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. . 2022; 235 - 240. 10.4274/nkmj.galenos.2022.96530
Vancouver Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. . 2022; 235 - 240. 10.4274/nkmj.galenos.2022.96530
IEEE Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g "Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki." , ss.235 - 240, 2022. 10.4274/nkmj.galenos.2022.96530
ISNAD Even, Özge vd. "Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki". (2022), 235-240. https://doi.org/10.4274/nkmj.galenos.2022.96530
APA Even Ö, ÇELIKKOL A, Bayrakci N, Karabacak V, özkan g (2022). Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. Namık Kemal Tıp Dergisi, 10(3), 235 - 240. 10.4274/nkmj.galenos.2022.96530
Chicago Even Özge,ÇELIKKOL ALIYE,Bayrakci Nergiz,Karabacak Veli Yakup,özkan gülsu Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. Namık Kemal Tıp Dergisi 10, no.3 (2022): 235 - 240. 10.4274/nkmj.galenos.2022.96530
MLA Even Özge,ÇELIKKOL ALIYE,Bayrakci Nergiz,Karabacak Veli Yakup,özkan gülsu Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. Namık Kemal Tıp Dergisi, vol.10, no.3, 2022, ss.235 - 240. 10.4274/nkmj.galenos.2022.96530
AMA Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. Namık Kemal Tıp Dergisi. 2022; 10(3): 235 - 240. 10.4274/nkmj.galenos.2022.96530
Vancouver Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki. Namık Kemal Tıp Dergisi. 2022; 10(3): 235 - 240. 10.4274/nkmj.galenos.2022.96530
IEEE Even Ö,ÇELIKKOL A,Bayrakci N,Karabacak V,özkan g "Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki." Namık Kemal Tıp Dergisi, 10, ss.235 - 240, 2022. 10.4274/nkmj.galenos.2022.96530
ISNAD Even, Özge vd. "Serum Magnezyum Düzeyi, Plazma Aterojenik İndeksi ve Glomerüler Filtrasyon Hızı Arasındaki İlişki". Namık Kemal Tıp Dergisi 10/3 (2022), 235-240. https://doi.org/10.4274/nkmj.galenos.2022.96530